Sutter Well being researchers have launched a biobank registry to speed up analysis into LATE, a lesser-known type of dementia that may mimic Alzheimer’s illness however stems from a unique underlying trigger.
The LATE Biobank Registry permits Sutter researchers to check organic samples and medical knowledge from sufferers who meet medical standards for LATE. By gathering samples over the course of sufferers’ care, researchers hope to raised perceive the illness, develop and validate biomarkers and lay the groundwork for future medical trials.
The LATE registry demonstrates the broader promise of the Sutter Biobank: connecting organic samples with wealthy medical data from sufferers receiving care throughout our system. By constructing analysis assets round ailments of getting old, we are able to examine why individuals expertise circumstances resembling dementia in a different way and speed up the seek for biomarkers and extra personalised approaches to prevention, prognosis and remedy.”
Greg Tranah, Ph.D., senior scientist and director, Sutter Biobank
Dr. Shawn Kile, chair of Sutter Well being’s Superior Neuroscience Service Line will current early findings from the registry Nov. 18 on the Medical Trials on Alzheimer’s Illness convention in Boston. His summary presentation, “Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Well being,” particulars the creation of the registry and its preliminary enrollment.
LATE, or limbic-predominant age-related TDP-43 encephalopathy, is related to an irregular buildup of the protein TDP-43 in areas of the mind crucial to reminiscence. In contrast to Alzheimer’s illness, LATE presently has no particular biomarkers or recognized therapies.
“Based mostly on post-mortem research, we’re studying that LATE pathology is exhibiting up in roughly 40% of individuals age 80 and older. That is vital. Whether or not that is the first driver of cognitive decline in some instances or co-pathology in different instances, it is very important perceive,” mentioned Dr. Kile. “By gathering blood and cerebrospinal fluid from clinically suspected instances over time, this biobank registry might help us shut present data gaps and, in the end, transfer towards a biomarker-driven prognosis and extra exact therapies for LATE.”
The Alzheimer’s Affiliation launched in 2025 medical standards for LATE. As biomarker testing makes it simpler to determine Alzheimer’s, researchers are additionally recognizing sufferers whose reminiscence loss resembles Alzheimer’s, however who check adverse for amyloid and tau biomarkers related to the illness. “A few of these sufferers could as an alternative have LATE,” says Dr. Kile.
Sutter’s LATE Biobank Registry opened for enrollment in Might 2026. On the time of summary submission, researchers had recognized 21 sufferers who met eligibility standards, with six consented to take part. Eligible sufferers can enroll via collaborating Sutter Well being associates throughout California. Because the registry grows, it additionally creates a cohort of sufferers for future medical trials of therapies concentrating on TDP-43.
“A well being system like Sutter can leverage their sufferers to advance dementia analysis, from figuring out sufferers in medical care and gathering samples over time to finding out new biomarkers and making ready for future trials. That connection between analysis and real-world care offers us an vital alternative to enhance how neurodegenerative ailments resembling LATE are acknowledged and, in the end, handled,” mentioned Armen Moughamian, M.D., Ph.D., chief of reminiscence for Sutter’s Neuroscience Service Line and medical director of Sutter’s Ray Dolby Mind Well being Heart at California Pacific Medical Heart.
